Valuation: Celcuity Inc.

Market Cap 4.31B 3.78B 3.52B 3.23B 6.07B 415B 6.16B 41.78B 16.32B 204B 16.17B 15.82B 705B P/E 2026 *
-21x
P/E 2027 * -176x
Enterprise Value 4.31B 3.78B 3.52B 3.23B 6.07B 415B 6.16B 41.78B 16.32B 204B 16.17B 15.82B 705B EV / Sales 2026 *
111x
EV / Sales 2027 * 11x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celcuity Inc.

1 day-6.50%
1 week-6.74%
Current month-21.22%
1 month-14.48%
3 months-31.90%
6 months-27.71%
Current year-17.37%
1 week 82.41
Extreme 82.41
92.66
1 month 82.41
Extreme 82.41
117.21
Current year 82.41
Extreme 82.41
151.02
1 year 13.59
Extreme 13.59
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 31/12/2011
Chief Executive Officer 64 31/12/2011
Director of Finance/CFO 59 30/06/2017
Director TitleAgeSince
Chairman 64 31/12/2011
Director/Board Member 64 31/12/2011
Director/Board Member 67 31/01/2014
Date Insider Type Main position Quantity % Market Cap.
14/07/26
Baker Bros. Advisors LP
SellCompany -3,100,000 6.6996%
10/06/26 Don

Director

-28,096 0.0607%
10/06/26 Don

Director

-25,006 0.0540%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-6.74%+486.62%+708.83% 4.31B
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-3.03%-2.07%-21.80%-16.29% 23.28B
-0.40%-0.93%+3.66%+424.49% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.33%-0.76%+23.90%+179.01% 13.99B
Average -1.53%+0.43%+86.27%+228.85% 24.63B
Weighted average by Cap. -0.94%+1.44%+50.42%+148.41%

Financials

2026 *2027 *
Net sales 38.87M 34.14M 31.75M 29.13M 54.73M 3.74B 55.58M 377M 147M 1.84B 146M 143M 6.36B 393M 346M 321M 295M 554M 37.88B 563M 3.82B 1.49B 18.63B 1.48B 1.44B 64.4B
Net income -221M -194M -181M -166M -311M -21.29B -316M -2.14B -838M -10.47B -830M -812M -36.2B -34.24M -30.07M -27.97M -25.66M -48.22M -3.3B -48.96M -332M -130M -1.62B -129M -126M -5.61B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
24/07/26 US$82.60 -6.50% 790,068
23/07/26 US$88.34 -2.00% 1,751,907
22/07/26 US$90.14 -1.69% 792,947
21/07/26 US$91.69 +4.21% 1,855,686
20/07/26 US$87.99 -0.44% 1,053,678
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
88.34USD
Average target price
163.45USD
Spread / Average Target
+85.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock